NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
Clinical Trials
10 trialsNCT00074269 2023-06-05
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
University of California, San Diego
Phase 2 Terminated
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00376805 2017-12-28
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01105650 2017-12-28
MT2009-30
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00523809 2013-01-28
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00048893 2012-04-13
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated